Dr. Mikhail Blagosklonny is a doctor, researcher, editor and professor based in New York. Dr. Blagosklonny’s areas of expertise are cancer and aging. He is highly regarded as a professor and an expert in his field by his peers and students.
His research specifically addresses cancer biology and therapy, and mechanisms of aging and anti-aging drugs. Dr. Blagosklonny’s renown is attributed to his exploration of how treatments can leverage the body’s ability to target and destroy specific cancer cells without harming other healthy cells (which occurs with traditional cancer treatments that target and harm all cells in the body).
Dr. Blagosklonny’s research interests in molecular and cellular biology include oncogenes, tumor suppressors, signal transduction, cell cycle, mitosis, apoptosis, anticancer therapeutics and more and learn more about Mikhail.
Dr. Blagosklonny’s fascinating research in progressive cancer treatments has investigated anticancer strategies which include the protection of normal (noncancerous) cells. Specifically, using drug combinations to selectively target cancer cells and shield healthy cells. This research has applications for the treatment of cancer patients, and also for anti-aging medicine. His research has explored the connection between cancer and aging, and why cancer risk increases with age and more information click here.
Dr. Blagosklonny holds an medical degree in internal medicine and a PhD in experimental medicine from First Pavlov State Medical University of St. Petersburg in Russia. Dr. Blagosklonny has taught as an associate professor at New York Medical College in Valhalla, NY, and at Roswell Park Cancer Institute in Buffalo, NY. He was a senior scientist at Ordway Research Institute Albany, NY and continues his research at Roswell Park Cancer Institute today and Mikhail’s lacrosse camp.
Dr. Blagosklonny has researched and published extensively – authoring over 270 peer-reviewed journal articles, reviews, and book chapters. He is highly involved in both writing and editing medical research, serving on the editorial board of several medical journals:
- Editor-in-Chief of “Oncotarget”
- Founding Editor and Editor-in-Chief of “Cell Cycle”
- Co-Editor and Co-Founder of “Aging”
- Associate Editor for “Cancer Biology & Therapy”, “Autophagy”, “Cancer Research”, “Cell Death and Differentiation”, “International Journal of Cancer”, “The American Journal of Pathology”, and “PLOS ONE”
Dr. Blagosklonny’s work with online journal Oncotarget expands on his professional goals to make innovative treatments more effective, less harmful, and less expensive. Oncotarget aims to make scientific results rapidly and widely available. The journal publishes articles weekly in the areas of Oncology, Neuroscience, Endocrinology, Cardiology, Metabolism, Cell Biology, and Pharmacology and read full article.
Dr. Blagosklonny’s work are not only making effective cancer treatments more humane, it is also making them more accessible. By reducing the harm and cost of cancer treatment, he aspires to make effective therapies accessible to all patients in need.